FGFR3

Chr 4ADAR

fibroblast growth factor receptor 3

Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation and apoptosis. Plays an essential role in the regulation of chondrocyte differentiation, proliferation and apoptosis, and is required for normal skeleton development. Regulates both osteogenesis and postnatal bone mineralization by osteoblasts. Promotes apoptosis in chondrocytes, but can also promote cancer cell proliferation. Required for normal development of the inner ear. Phosphorylates PLCG1, CBL and FRS2. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Plays a role in the regulation of vitamin D metabolism. Mutations that lead to constitutive kinase activation or impair normal FGFR3 maturation, internalization and degradation lead to aberrant signaling. Over-expressed or constitutively activated FGFR3 promotes activation of PTPN11/SHP2, STAT1, STAT5A and STAT5B. Secreted isoform 3 retains its capacity to bind FGF1 and FGF2 and hence may interfere with FGF signaling

Primary Disease Associations & Inheritance

AchondroplasiaMIM #100800
AD
Bladder cancer, somaticMIM #109800
CATSHL syndromeMIM #610474
ADAR
Cervical cancer, somaticMIM #603956
Colorectal cancer, somaticMIM #114500
Crouzon syndrome with acanthosis nigricansMIM #612247
AD
HypochondroplasiaMIM #146000
AD
LADD syndrome 2MIM #620192
AD
Muenke syndromeMIM #602849
AD
Nevus, epidermal, somaticMIM #162900
AD
Spermatocytic seminoma, somaticMIM #273300
Thanatophoric dysplasia, type IMIM #187600
AD
Thanatophoric dysplasia, type IIMIM #187601
AD
UniProtCamptodactyly, tall stature, and hearing loss syndrome
UniProtMultiple myeloma
UniProtLacrimo-auriculo-dento-digital syndrome 2
UniProtKeratinocytic non-epidermolytic nevus
1378
ClinVar variants
35
Pathogenic / LP
0.00
pLI score
12
Active trials
Clinical SummaryFGFR3
Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
35 Pathogenic / Likely Pathogenic· 262 VUS of 1378 total submissions
💊
Clinical Trials
12 active or recruiting trials — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
0.60LOEUF
pLI 0.000
Z-score 3.48
OE 0.39 (0.260.60)
Tolerant

Typical tolerance to LoF variation

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
1.26Z-score
OE missense 0.85 (0.780.92)
458 obs / 540.2 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.39 (0.260.60)
00.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.0.85 (0.780.92)
00.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.1.27
01.21.6
LoF obs/exp: 15 / 38.2Missense obs/exp: 458 / 540.2Syn Z: -3.39

ClinVar Variant Classifications

1378 submitted variants in ClinVar

Classification Summary

Pathogenic31
Likely Pathogenic4
VUS262
Likely Benign179
Benign6
Conflicting3
31
Pathogenic
4
Likely Pathogenic
262
VUS
179
Likely Benign
6
Benign
3
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
3
28
0
31
Likely Pathogenic
1
1
2
0
4
VUS
13
219
24
6
262
Likely Benign
0
20
60
99
179
Benign
0
0
5
1
6
Conflicting
3
Total14243119106485

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

FGFR3 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Gene2Phenotype Curations

FGFR3-related achondroplasia

definitive
ADGain Of FunctionAltered Gene Product Structure
Dev. DisordersSkeletal
G2P ↗

FGFR3-related camptodactyly tall stature and hearing loss syndrome

definitive
ADUndeterminedAltered Gene Product Structure
Dev. DisordersSkeletal
G2P ↗
missense variantinframe deletioninframe insertion

FGFR3-related thanatophoric dysplasia, type 1

definitive
ADGain Of FunctionAltered Gene Product Structure
Dev. DisordersSkeletal
G2P ↗

FGFR3-related thanatophoric dysplasia, type 2

definitive
ADGain Of FunctionAltered Gene Product Structure
Dev. DisordersSkeletal
G2P ↗

FGFR3-related hypochondroplasia

definitive
ADGain Of FunctionAltered Gene Product Structure
Dev. DisordersSkeletal
G2P ↗

FGFR3-related Muenke syndrome

definitive
ADGain Of FunctionAltered Gene Product Structure
Dev. DisordersSkeletal
G2P ↗

FGFR3-related lacrimo-auriculo-dento-digital syndrome (LADD)

definitive
ADUndeterminedAltered Gene Product Structure
Dev. DisordersEyeSkeletal
G2P ↗
missense variantinframe deletioninframe insertion

FGFR3-related Crouzon syndrome with acanthosis nigricans

definitive
ADGain Of FunctionAltered Gene Product Structure
Dev. DisordersSkinSkeletal
G2P ↗
missense variant

Gene2Phenotype curations · DECIPHER consortium patient cohort (public variants) · deciphergenomics.org

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

Achondroplasia

MIM #100800

Molecular basis of disorder known

Autosomal dominant

Bladder cancer, somatic

MIM #109800

Molecular basis of disorder known

CATSHL syndrome

MIM #610474

Molecular basis of disorder known

Autosomal dominantAutosomal recessive

Cervical cancer, somatic

MIM #603956

Molecular basis of disorder known

Colorectal cancer, somatic

MIM #114500

Molecular basis of disorder known

Crouzon syndrome with acanthosis nigricans

MIM #612247

Molecular basis of disorder known

Autosomal dominant

Hypochondroplasia

MIM #146000

Molecular basis of disorder known

Autosomal dominant

LADD syndrome 2

MIM #620192

Molecular basis of disorder known

Autosomal dominant

Muenke syndrome

MIM #602849

Molecular basis of disorder known

Autosomal dominant

Nevus, epidermal, somatic

MIM #162900

Molecular basis of disorder known

SADDAN

MIM #616482

Molecular basis of disorder known

Autosomal dominant

Spermatocytic seminoma, somatic

MIM #273300

Molecular basis of disorder known

Thanatophoric dysplasia, type I

MIM #187600

Molecular basis of disorder known

Autosomal dominant

Thanatophoric dysplasia, type II

MIM #187601

Molecular basis of disorder known

Autosomal dominant
Clinical Literature
Landmark / reviewRecent case evidence

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

HER2-Gastric/Gastroesophageal Junction CancerUrothelial CarcinomaNon-Small Cell Lung Cancer

A Phase 2 Clinical Study of ABSK061 and ABSK043

RECRUITING
NCT06632262Phase PHASE2Abbisko Therapeutics Co, LtdStarted 2024-11-13
ABSK061 + ABSK043ABSK061+ABSK043 in combination with CAPOX
Healthy

A Relative Bioavailability and Food Effect Study of TYRA-300-B01 Capsule and Tablet Formulations in Healthy Adult Participants

ACTIVE NOT RECRUITING
NCT06006702Phase PHASE1Tyra Biosciences, IncStarted 2023-10-16
TYRA-300-B01
Advanced Malignant Solid NeoplasmAnn Arbor Stage III Non-Hodgkin LymphomaAnn Arbor Stage IV Non-Hodgkin Lymphoma

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

ACTIVE NOT RECRUITING
NCT03155620Phase PHASE2National Cancer Institute (NCI)Started 2017-07-31
Biopsy ProcedureBiospecimen CollectionBone Marrow Aspiration and Biopsy
Intrahepatic Cholangiocarcinoma (Icc)CholangiocarcinomaOther Solid Tumors, Adult

A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

RECRUITING
NCT06777316Phase PHASE1, PHASE2Cogent Biosciences, Inc.Started 2025-01-22
CGT4859
Lymphoma, Non-HodgkinMultiple MyelomaAdvanced Solid Tumors

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

RECRUITING
NCT03297606Phase PHASE2Canadian Cancer Trials GroupStarted 2018-03-23
OlaparibDasatinibNivolumab plus Ipilimumab
Low-grade NMIBCFGFR Gene AmplificationFGFR Gene Alterations

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

RECRUITING
NCT06995677Phase PHASE2Tyra Biosciences, IncStarted 2025-06-27
TYRA-300 60mgTYRA-300 50mgTYRA-300 Dose TBD
Urothelial Carcinoma (UC)Bladder (Urothelial, Transitional Cell) CancerLiquid Biopsy

Using Liquid Biopsy Testing to Identify, Monitor, Predict Recurrence in Urothelial Carcinoma

RECRUITING
NCT07441499Tianjin Medical University Second HospitalStarted 2026-03
Multi-Component Liquid Biopsy for Urothelial Carcinoma
Low Grade Upper Tract Urothelial Carcinoma

Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma

RECRUITING
NCT07265947Phase PHASE2Tyra Biosciences, IncStarted 2025-12-22
Dabogratinib (TYRA-300) 60mgDabogratinib (TYRA-300) 80mgDabogratinib (TYRA-300) TBD
Urinary Bladder NeoplasmsNeoplasm MetastasisUreteral Neoplasms

FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

RECRUITING
NCT05614739Phase PHASE1Eli Lilly and CompanyStarted 2023-01-12
LOXO-435Pembrolizumabenfortumab vedotin
Metastatic Hepatocellular CarcinomaSolid TumorsSolid Tumor, Adult

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

RECRUITING
NCT06915753Phase PHASE1Tyra Biosciences, IncStarted 2025-04-24
TYRA-430
Bladder CancerBladder Cancer RecurrenceAdjuvant Therapy for Bladder Cancer

Multiplex Mutation Detection Using Mass Spectrometry in Bladder Cancer

RECRUITING
NCT07424560Zhilong DongStarted 2026-02-25
Multiplex Mutation Detection System for Bladder Cancer (Nucleic Acid Mass Spectrometry)
Non-Muscle Invasive Bladder Urothelial CarcinomaRecurrent Non-Muscle Invasive Bladder Urothelial Carcinoma

Study to Determine Possible Effects of Apalutamide, Compared to Placebo, on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer

NOT YET RECRUITING
NCT05521698Phase PHASE1University of Wisconsin, MadisonStarted 2026-04
ApalutamideBiopsy ProcedureBiospecimen Collection